The compounds of the present invention are represented by the following compounds having Formula I:
The compounds of the present invention are represented by the following compounds having Formula I:
The compounds of the present invention are represented by the following compounds having Formula I:
where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic):
The compounds of the present invention are represented by the following compounds having Formula I:
where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic):
The compounds of the present invention are represented by the following compounds having Formula I:
where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic):
where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein.
The compounds of the present invention are represented by the following compounds having Formula I:
where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic):
where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein.
These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
C07C 237/06 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
C07C 237/12 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone acyclique d'un radical hydrocarboné substitué par des groupes carboxyle
C07C 237/22 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné ayant des atomes d'azote de groupes amino liés au squelette carboné de la partie acide, en outre acylés
C07C 271/22 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des groupes carboxyle
C07C 311/14 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons
C07C 311/19 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique à un atome de carbone acyclique d'un radical hydrocarboné substitué par des groupes carboxyle
C07D 209/18 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 261/18 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
An integrated circuit includes a programmable reflective load line that includes main delay segments arranged in series between an input of the programmable reflective load line and ground, variable delay modules arranged in parallel between nodes adjoining the main delay segments and ground, and main switches, with each main switch arranged between one of the variable delay modules and one of the nodes adjoining the main delay segments. Each variable delay module includes sub-delay segments arranged in series between the associated main switch and ground. Each variable delay module also includes one or more sub-delay switches, with each sub-delay switch arranged between a node adjoining two of the associated sub-delay segments and ground. The integrated circuit may further include a hybrid coupler arranged with the programmable reflective load line and another programmable reflective load line as a reflective-type phase-shifter.
H03K 5/133 - Dispositions ayant une sortie unique et transformant les signaux d'entrée en impulsions délivrées à des intervalles de temps désirés utilisant une chaîne de dispositifs actifs de retard
H03K 5/00 - Transformation d'impulsions non couvertes par l'un des autres groupes principaux de la présente sous-classe
Disclosed herein are immunomodulatory nanoparticle conjugates useful for therapeutics and/or diagnostics. In certain embodiments, each immunomodulatory nanoparticle conjugate comprises a nanoparticle that has a plurality of cellular receptor- and/or antigen- targeting ligands (e.g., wherein the plurality of cellular receptor- and/or antigen- targeting ligands targets domains that are expressed on the surface of tumor cells, e.g., wherein the plurality of cellular receptor- and/or antigen- targeting ligands targets MUC16ecto domain expressed on the surface of tumor cells, e.g., wherein the plurality of cellular receptor- and/or antigen- targeting ligands comprises anti-MUC16, e.g., wherein the plurality of cellular receptor- and/or antigen- targeting ligands comprises a plurality of immunomodulatory/stimulatory ligands (of the same species or of differing species) (e.g., a plurality of oligodeoxynucleotides (ODNs) (e.g., an ODN containing an unmethylated cytosine-phosphate-guanine (CpG) motif (or CpG ODNs)) conjugated to the nanoparticle) conjugated to the nanoparticle.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
Wearable compression systems, which may comprise one or more or a plurality of actuator(s) embedded within a textile structure and may be configured to provide a compression function to a therapy target of an individual. Wearable compression systems may comprise a circuit or the like. Methods of operating a wearable compression system. Methods of designing (e.g., automatically designing) wearable compression systems. Methods of designing may comprise receiving a set of measurements, generating default dimensions, default number of actuators, and/or default actuator locations for a wearable compression system and/or a graphical representation of same, optionally modifying default dimensions, default number of actuators, and/or default actuator locations, updating the wearable compression system and/or graphical representation of same, and generating an instruction file. Methods of treating edema or symptoms of edema.
Systems, methods, and computer program products are provided for diagnosing, prognosing, or monitoring cancer in a subject, particularly the assessment of minimal residual disease (MRD).
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
6.
ULTRASMALL NANOPARTICLES AND METHODS OF MAKING AND USING SAME
An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core-shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.
Technologies for radiomyography gesture recognition include a computing device coupled to a radio near-field sensor device including multiple transmitting and receiving antennas. The computing device transmits multiple radio frequency signals with the sensor device, which is positioned near the muscle area of interest for a user. The sensor device may include a cuff or armband that surrounds the forearm of the user. The computing device receives multiple time-domain signals with the receiving antennas and classifies the signals with a trained machine learning model to generate one or more distinct states, such as a gesture or posture classification. The computing device may transform each time-domain signal to a two-dimensional spectrogram and classify the two-dimensional spectrogram with a vision-based model such as a vision transformer model. Other embodiments are described and claimed.
Centre National de la Recherche Scientifique (CNRS) (France)
UNIVERSITÉ DE STRASBOURG (France)
Cornell University (USA)
Université Paris-Saclay (France)
Assistance Publique-Hopitaux de Paris (APHP) (France)
Inventeur(s)
Puccio, Hélène Monique
Aubourg, Patrick
Crystal, Ronald G.
Bougneres, Pierre
Abrégé
The present invention relates to a method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence of a gene that can restore energy failure. More particularly, the invention relates to a method for preventing or treating a cardiomyopathy associated with Friedreich ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a frataxin (FXN) encoding nucleic acid.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A multi-color spaceplate includes a first component spaceplate and a second component spaceplate cascaded with the first component spaceplate. The first component spaceplate has an on-resonance compression ratio C11 at a first resonance wavelength and, at a second resonance wavelength, an off-resonance compression ratio C21, less than on-resonance compression ratio C11. The second component spaceplate has an on-resonance compression ratio C22 at the second resonance wavelength and, at the first resonance wavelength, an off-resonance compression ratio C12 less than on-resonance compression ratio C22. The multi-color spaceplate may include a third component spaceplate, cascaded with the first and second component spaceplates, and having: (i) an on-resonance compression ratio C33 at a third resonance wavelength, (ii) at the first resonance wavelength, an off-resonance compression ratio C13 that is less than on-resonance compression ratio C33, and (iii) at the second resonance wavelength, an off-resonance compression ratio C23 less than on-resonance compression ratio C33.
G02F 1/29 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de la position ou de la direction des rayons lumineux, c.-à-d. déflexion
10.
ZWITTERIONIC LIPID NANOPARTICLE COMPOSITIONS, AND METHODS OF USE
A lipid nanoparticle (LNP) composition comprising: (i) at least one zwitterionic polymer-containing lipid in which a lipid moiety is covalently attached to a zwitterionic polymer, wherein the zwitterionic polymer has a molecular weight of no more than or less than 3 kDa or 2 kDa; (ii) at least one non-cationic lipid (e.g., selected from charged and uncharged lipids, but may or may not be attached to a polymer); (iii) at least one non-cationic lipid; and (iv) at least one therapeutic substance. The LNP composition may optionally include a cationic or ionizable lipid and/or cholesterol or derivative thereof. Also described herein are methods of delivering a therapeutic substance to a subject, such as an mRNA, the method comprising administering to the subject a lipid nanoparticle composition described above.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
Graphitic-material-coated silicon particles and uses thereof and compositions thereof and methods of making graphitic-material-coated silicon particles. In various examples, a method of forming a plurality of graphitic-material-coated silicon particles comprises milling (e.g., air jet ball milling or the like) a mixture comprising one or more silicon particle(s), one or more graphitic material(s) (e.g., graphite, graphene, or the like, or any combination thereof), and one or more binder(s). In various examples, a graphitic-material-coated silicon particle comprises a silicon particle and one or more graphitic material(s), where the one or more graphitic material(s) is/are disposed on at least a portion, substantially all, or all of one or more surface(s) of the silicon particle. In various examples, an electrode or device (such as, for example, an electrochemical device or the like) comprises a plurality of graphitic-material-coated silicon particles.
B02C 17/18 - Désagrégation au tonneau, c.-à-d. par des appareils constitués par une cuve où les produits à désagréger sont chargés, avec ou sans éléments particuliers de désagrégation tels que billes ou boulets Parties constitutives
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
12.
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE
Centre National de la Recherche Scientifique (CNRS) (France)
UNIVERSITÉ DE STRASBOURG (France)
Cornell University (USA)
Université Paris-Saclay (France)
Assistance Publique-Hopitaux de Paris (APHP) (France)
Inventeur(s)
Puccio, Hélène Monique
Aubourg, Patrick
Crystal, Ronald G.
Bougneres, Pierre
Abrégé
A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
42 - Services scientifiques, technologiques et industriels, recherche et conception
09 - Appareils et instruments scientifiques et électriques
Produits et services
Research and design of photovoltaic systems; consultancy in the field of photovoltaic systems; research and design of tensile fabric substrates bearing photovoltaic cells; research and design of polymorphic photovoltaic structures; research and design of shape-changing photovoltaic systems; research and design of solar tracking systems, actuators and control algorithms Photovoltaic systems that convert sunlight into electricity energy; flexible substrates bearing photovoltaic cells; polymorphic substrates bearing photovoltaic cells; actuators and control algorithms for changing a shape of polymorphic substrates bearing photovoltaic cells; solar canopies incorporating solar cells; building-applied fabrics bearing photovoltaic cells for the collection of solar energy; architectural fabrics embedded with photovoltaic cells; photovoltaic systems comprised of photovoltaic tensile fabrics
14.
BIDIRECTIONAL IMPEDANCE CONTROL NETWORK-BASED AC-DC CONVERTER WITH REACTIVE POWER CAPABILITY
A bidirectional converter includes a first rectifier circuit, a first and second half-bridge inverter circuits, an isolation transformer, a second rectifier circuit, and a network coupled between the half-bridge inverter circuits and the isolation transformer. The network forms an impedance control network (ICN) when the bidirectional converter is operated in a forward operation mode and forms a resistance compression network (RCN) when the bidirectional converter is operated in a reverse operation mode. The bidirectional converter also includes an inductive element established across terminals of the isolation transformer. The inductance of the inductive element, the differential reactance of the network, and the turns ratio of the isolation transformer are determined to ensure zero voltage switching of the high frequency transistors of the bidirectional converter. Additionally, zero voltage switching is promoted by controlling the phase shift between the first and second half-bridge inverter circuits and between legs of the second rectifier circuit.
H02M 7/797 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continuTransformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif avec possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
H02M 1/00 - Détails d'appareils pour transformation
H02M 7/217 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continu sans possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
H02M 7/5387 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif sans possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs, p. ex. onduleurs à impulsions à un seul commutateur dans une configuration en pont
A regenerative amplifier includes a plurality of reflective elements, a doped optical fiber, and an optical switch. The plurality of reflective elements form an optical cavity having a plurality of optical-cavity modes. The doped optical fiber is located within the optical cavity and has a plurality of waveguide modes. The optical switch is located within the optical cavity and is controllable between first and second states. In the first state, the optical switch transmits light exiting the doped optical fiber such that the light resonates within the optical cavity. In the second state, the optical switch one or both of (i) couples a seed pulse into the optical cavity and (ii) couples an amplified pulse out of the optical cavity An optical-cavity mode, of the plurality of optical-cavity modes, having the lowest loss and highest gain includes a mode of the plurality of waveguide modes.
16.
METHOD FOR RELATIVE QUANTIFICATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, OR COPY CHANGES, USING COMBINED NUCLEASE, LIGATION, AND POLYMERASE REACTIONS
The present invention is directed to kits for identifying the presence of one or more target nucleotide sequences in a sample that involve a ligation and/or polymerase reaction. In some embodiments, the ligation products formed in the ligation process of the present invention are subsequently amplified using a polymerase chain reaction. The ligated product sequences or extension products thereof are detected, and the presence of one or more target nucleotide sequences in the sample is identified based on the detection.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
CORNELL UNIVERSITY (USA)
Inventeur(s)
Savani, Rashmin
Aguilar-Carreño, Hector
Gludish, David
Abrégé
The present invention provides methods for treating a disease or disorder associated with inflammation and/or with TLR signaling and/or with NLRP3 inflammasome activation in a subject. The methods involve administering to the subject a pharmaceutical composition comprising a RHAMM-derived peptide or a RHAMM-derived peptide mimetic.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
Compounds, compositions including one or more of the compound(s), and methods of using the compounds and the compositions. The compounds comprise an (I) group. In various examples, a compound is an Acyl Protein Thioesterase 1 inhibitor (APT1 inhibitor) and/or an Acyl Protein Thioesterase 2 inhibitor (APT2 inhibitor). Compound(s) or composition(s), which may be pharmaceutical composition(s), can be used in methods of treating diseases or disorders, such as, for example, autoimmune disorders, neurodegenerative disorders, inflammatory disorders, and immune-mediated cancer diseases.
Compounds, compositions including one or more of the compound(s), and methods of using the compounds and the compositions. The compounds comprise an (I) group. In various examples, a compound is an Acyl Protein Thioesterase 1 inhibitor (APT1 inhibitor) and/or an Acyl Protein Thioesterase 2 inhibitor (APT2 inhibitor). Compound(s) or composition(s), which may be pharmaceutical composition(s), can be used in methods of treating diseases or disorders, such as, for example, autoimmune disorders, neurodegenerative disorders, inflammatory disorders, and immune-mediated cancer diseases.
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07F 9/6558 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun
19.
SYSTEM AND METHOD FOR EVALUATING THE BRAIN'S RESPONSE TO SPOKEN LANGUAGE
U.S. GOVERNMENT AS REPRESENTED BY THE DEPT. OF VETERANS AFFAIRS (USA)
Inventeur(s)
Shah, Sudhin A.
Schiff, Nicholas D.
Hill, Nicholas Jeremy
O'Sullivan, James A.
Lalor, Edmund C.
Abrégé
The system and methods described herein diagnose the semantic processing capability of a subject by measuring the neural response of the subject to one or more naturalistic speech stimuli. The system measures the subject's temporal response function to the naturalistic speech by computing a statistical comparison between the subject's neural signal and a time series of semantic metric values corresponding to a transcript of the naturalistic speech stimulus. A diagnosis of the subject's semantic processing capability is then made based on an evaluation of the statistical comparison.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
20.
CATIONIC POLYMERIZATION METHODS, POLYMERIZABLE COMPOSITIONS, AND PRODUCTS THEREOF
Polymers, polymerizable compositions, methods of making polymers, and uses of the polymers and compositions. In various examples, a polymer comprises a desirable ratio of cis groups to trans groups. In various examples, a method is an acid-catalyzed cationic polymerization using hydrogen bond donor(s) (HBD(s)), where one or more or all of the hydrogen bond donor(s) is/are chiral HBD(s). In various examples, an acid is formed in-situ (e.g., by irradiation of a polymerization agent (such as, for example, a photoacid generator or the like)). In various examples, an irradiation is carried out in a pre-determined pattern. In various examples, a polymer or a cationic polymerization product(s) formed by a method of the present disclosure is a sealant, an adhesive, a consumer product, a photoresist, a thermoplastic elastomer, or a component thereof, or the like.
C08G 59/42 - Acides polycarboxyliquesLeurs anhydrides, halogénures ou esters à bas poids moléculaire
C08G 59/40 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les agents de durcissement utilisés
21.
IMAGING SYSTEMS AND METHODS FOR TISSUE DIFFERENTIATION, E.G., FOR INTRAOPERATIVE VISUALIZATION
Described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C′ dots) to graphically differentiate specific nerves (e.g., sensory nerves vs. motor nerves) for nerve transplants and other surgeries. Also described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C′ dots) to graphically differentiate between different types of lymph nodes and/or lymphatic pathways, e.g., to safely and effectively perform vascularized lymph node transplantation in the treatment of lymphedema. Also described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C′ dots) to graphically differentiate parathyroid tissue.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
22.
DECENTRALIZED TECHNIQUES FOR VERIFICATION OF DATA IN TRANSPORT LAYER SECURITY AND OTHER CONTEXTS
A verifier device in one embodiment is configured to communicate over one or more networks with a client device and a server device. The verifier device participates in a three-party handshake protocol with the client device and the server device in which the verifier device and the client device obtain respective shares of a session key of a secure session with the server device. The verifier device receives from the client device a commitment relating to the secure session with the server device, and responsive to receipt of the commitment, releases to the client device additional information relating to the secure session that was not previously accessible to the client device. The verifier device verifies correctness of at least one characterization of data obtained by the client device from the server device as part of the secure session, based at least in part on the commitment and the additional information.
The present disclosure relates to a minigene cassette comprising, from 5' to 3': a first intron, an alternatively-spliced exon, and a second intron comprising a U1 binding sequence, where (i) a portion of the alternatively-spliced exon is complementary to a portion of the second intron; the portion of the alternatively-spliced exon that is complementary to the portion of the second intron forms a hairpin loop structure comprising a hairpin stem and a hairpin loop; the hairpin stem comprises at least a portion of the U1 binding sequence; and the hairpin loop comprises an aptamer or (ii) a portion of the second intron forms a hairpin loop structure comprising a hairpin stem and a hairpin loop; the hairpin stem comprises at least a portion of the U1 binding sequence; and the hairpin loop comprises an aptamer. Also disclosed are polynucleotides encoding such minigene cassettes and methods of use thereof.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
Described herein are methods and compositions that include use of one or more poly (ADP-ribose) polymerase 1 (PARP1) inhibitors and one or more inhibitors of activated stromal/activated cancer-associated fibroblasts. Such methods and compositions are useful for treating cancer. Further disclosed are PARP1 inhibitors, and inhibitors of activated stromal/activated cancer-associated fibroblasts used for the methods.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
25.
POLYMER NANOPARTICLES VIA CONDENSED DROPLET POLYMERIZATION
Provided is a method of synthesizing polymer particles, including: introducing vapor-phase reagents into a reactor having a substrate; forming condensed droplets of the reagents on the substrate; initiating polymerization; and polymerizing the condensed droplets of the reagents, thereby forming polymer particles. Polymer particles are also provided, including those incorporating therapeutic agents.
C08F 220/28 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle ne contenant pas de cycles aromatiques dans la partie alcool
C08F 226/06 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par un hétérocycle contenant de l'azote
A method for delivery of a nucleic acid. comprising administering a lipid nanoparticle composition loaded with the nucleic acid to a subject in which monocytes and/or macrophages have been depleted. thereby delivering the nucleic acid into the subject, the method may more particularly be practiced according to the following steps: a) depleting monocytes and/or macrophages in a subject: and b) administering a lipid nanoparticle composition loaded with the nucleic acid to the subject, thereby delivering the nucleic acid into the subject.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/663 - Composés ayant plusieurs groupes acide du phosphore ou leurs esters, p. ex. acide clodronique, acide pamidronique
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
27.
COMPOSITIONS AND METHODS FOR SOLUBILIZING GLYCOSYLTRANSFERASES
The present disclosure relates to a nucleic acid construct having a chimeric nucleic acid molecule encoding a tripartite glycosyltransferase fusion protein. The chimeric nucleic acid molecule includes a first nucleic acid moiety encoding an amphipathic shield domain protein; a second nucleic acid moiety encoding a glycosyltransferase; and a third nucleic acid moiety encoding a water soluble expression decoy protein. The first nucleic acid moiety is coupled to the second nucleic acid moiety's 3′ end and the third nucleic acid moiety is coupled to the second nucleic acid moiety's 5′ end. The coupling may be direct or indirect. The present disclosure further relates to an expression vector, a host cell, and a tripartite glycosyltransferase fusion protein encoded by the nucleic acid construct. Also disclosed are methods of recombinantly producing a tripartite glycosyltransferase fusion protein in soluble form and methods of cell-free glycan remodeling.
The present disclosure relates to a microfluidic circuit comprising a drug inlet port; an outlet port; a drug inlet main channel fluidically connecting the drug inlet port and the outlet port, where said drug inlet main channel comprises (i) a plurality of serpentine mixers and (ii) a plurality of dead-end first microchamber sets; a negative inlet port; a negative inlet main channel fluidically connecting the negative inlet port and the drug inlet main channel; a plurality (n) of ladder channels, where each of the plurality (n) of the ladder channels is fluidically connected to both the drug inlet main channel and the negative inlet main channel; and an outlet channel fluidically connected to the drug inlet main channel between the drug inlet port and the outlet port. Also disclosed is a microfluidic device comprising a microfluidic circuit of the present disclosure and a method for performing an assay.
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
The present disclosure relates to use of DNA methylation states of retroelements as an epigenetic biomarker of aging. Disclosed herein are retroelement-based epigenetic clocks, and methods for determining age (epigenetic, biological or chronological) of a subject by measuring DNA methylation status at CpG loci located in at least one retroelement. Also, disclosed are methods of treatment, prevention, assessing impact or efficacy, and prediction of outcome based on epigenetic age determinations made in accordance with the described methods and using retroelement-based epigenetic clocks. Also disclosed is use of an antiretroviral therapy for treatment of an age-associated disease or condition, rejuvenation and/or reducing epigenetic age.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
30.
WEARABLE DEVICES WITH WIRELESS TRANSMITTER-RECEIVER PAIRS FOR ACOUSTIC SENSING OF USER CHARACTERISTICS
An apparatus in one embodiment comprises at least one wearable device, with the at least one wearable device comprising at least one of a transmitter and a receiver of a wireless transmitter-receiver pair. The transmitter of the wireless transmitter-receiver pair transmits an acoustic signal, and the receiver of the wireless transmitter-receiver pair receives the acoustic signal. The received acoustic signal is processed utilizing a machine learning system to detect at least one characteristic of a user of the at least one wearable device. In some embodiments, a given wearable device comprises at least first and second wireless transmitter-receiver pairs, with the transmitter of each of the first and second wireless transmitter-receiver pairs transmitting an acoustic signal having a different carrier frequency. In such embodiments, a multi-channel echo profile may be generated using the multiple acoustic signals and classified by the machine learning system to detect the at least one characteristic.
Technologies for microwave annealing include a chamber, a heating device configured to heat a substrate borne within the chamber during system operation, a microwave source configured to direct microwave energy at a predetermined frequency to a location within the chamber at which the substrate is disposed, and an elongated waveguide disposed within the chamber and extending between the microwave source and the location within the chamber at which the substrate is disposed. The substrate may be a semiconductor doped by ion implantation or epitaxial growth. During operation, the microwave energy activates a dopant and/or breaks up a defect cluster within the substrate.
H01L 21/324 - Traitement thermique pour modifier les propriétés des corps semi-conducteurs, p. ex. recuit, frittage
H01L 21/66 - Test ou mesure durant la fabrication ou le traitement
H01L 21/67 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitementAppareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants
H05B 6/68 - Circuits pour le contrôle ou la commande
32.
Treatment of Proliferative Disorders Using Antibodies to PSMA
Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA after first administering a hormonal therapy.
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
33.
METHODS FOR CARBON DIOXIDE SEPARATION AND MATERIALS AND SYSTEMS FOR SAME
22, or any combination thereof. A method may comprise irradiating, with electromagnetic radiation, a capture sorbent comprising one or more 2-alkyl phenyl ketone(s) and/or group(s) formed therefrom and one or more compound(s) of interest, where at least a portion of the compound(s) of interest react with at least a portion of the 2-alkyl phenyl ketone(s) and/or group(s) formed therefrom to form one or more cycloaddition product(s). A method may further comprise releasing at least a portion of one or more compound(s) of interest from one or more cycloaddition product(s). Capture sorbent materials for separating one or more compound(s) of interest, which may comprise a capture sorbent comprising one or more 2-alkyl phenyl ketone(s) and/or group(s) formed therefrom and a substrate. Systems for capture and optionally, isolation, of one or more compound(s) of interest, which may comprise one or more 2-alkyl phenyl ketone(s) and/or group(s) formed therefrom.
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
34.
ULTRASMALL IMMUNE CELL BASED PARTICLE IMMUNOTHERAPIES, IMMUNE CELL COMPOSITIONS, AND USES THEREOF
Disclosed herein are compositions comprising engineered immune cells and immunomodulatory nanoparticles for localized targeted therapy in the treatment of cancer and other diseases, injuries, or conditions. The engineered immune cells comprise chimeric antigen receptors (CARs) that secrete bispecific immune cell engager (e.g., bispecific T cell Engagers ("BiTEs"), e.g., a bispecific macrophage engager, e.g., a bispecific neutrophil engager). The CAR.bispecific immune cell engager engineered immune cells are combined with silica nanoparticles (with or without the immune cell engager targeting ligands attached thereto) for combinatorial treatment of the disease or condition.
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p. ex. un ion inorganique complexé avec l’ingrédient actif
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
Methods for forming films, films, and uses thereof. In various examples, a method comprises forming a film using a deposition solution comprising two or more multiblock copolymers, where the multiblock copolymers each comprise different corona-forming block(s) or different corona-forming block(s) and different core-forming block(s), where there is no substantial exchange of the polymer chains between the micelles formed from the multiblock copolymers. In various examples, a film comprises an isoporous top surface layer comprising two or more multiblock copolymers and an asymmetric layer, which may be an asymmetric substructure, where at least a portion the core blocks of the multiblock copolymers are isotropically or statistically distributed in, disposed in a plurality of distinct domains of, or disposed in a three-dimensional lattice in (or forming) at least a portion of the pore wall surface(s) of the isoporous surface layer. In various examples, a film is used in a filtration, separation, or catalytic application.
B01D 71/44 - Polymères obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, non prévus dans un seul des groupes
B01D 71/82 - Matériaux macromoléculaires non prévus spécifiquement dans un seul des groupes caractérisés par la présence de groupes déterminés, p. ex. introduits par un post-traitement chimique
C08G 18/63 - Polymères séquencés ou greffés obtenus par polymérisation de composés contenant des doubles liaisons carbone-carbone sur des polymères
C08L 53/00 - Compositions contenant des copolymères séquencés possédant au moins une séquence d'un polymère obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carboneCompositions contenant des dérivés de tels polymères
BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (USA)
CORNELL UNIVERSITY (USA)
Inventeur(s)
Martin, Gregory B.
Feder, Ari
Mainiero, Samantha
Hind, Sarah
Mazo Molina, Diana Carolina
Abrégé
Embodiments of the disclosure are directed to compositions and methods for enhancing disease resistance in plants. One aspect of embodiments of the disclosure relates to a nucleic acid construct comprising a nucleic acid molecule comprising a Pseudomonas tomato race 1 (Ptr1) polynucleotide, a 5′ heterologous DNA promoter sequence, and a 3′ terminator sequence, wherein the nucleic acid molecule, the DNA promoter sequence, and the terminator sequence are operatively coupled to permit transcription of the nucleic acid molecule. Methods of imparting disease resistance to a plant and methods of identifying a candidate plant suitable for breeding that displays enhanced disease resistance are also disclosed. Embodiments of the disclosure also include plant cells, plants, and plant seeds including a heterologous Pseudomonas tomato race 1 (Ptr1) polynucleotide.
A01H 6/82 - Solanaceae, p. ex. poivron, tabac, pomme de terre, tomate ou aubergine
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
37.
GENE SIGNATURE PANEL PREDICTING CANCER RESPONSE TO IMMUNE CHECKPOINT BLOCKADE AND RADIATION THERAPY
The present disclosure relates to the identification of gene signature panels and tumor characteristics for predicting solid tumors (e.g., lung cancer) response to immune checkpoint blockade and/or radiation therapy, and methods of uses thereof.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
38.
THERMOSET MATERIALS AND METHODS OF MAKING AND USING SAME
Thermoset materials and compositions thereof, and methods of making and using same. A thermoset material comprises one or more polymeric group(s) and one or more crosslinking groups. The polymeric group(s) and crosslinking group(s) are least partially formed from the same monomer(s). In various examples, a thermoset material is formed by a method comprising a first polymerization (such as, for example a ring-opening metathesis polymerization (ROMP), an acyclic diene metathesis (ADMET) polymerization, or the like) and a second polymerization (such as, for example, a cationic polymerization, a radical polymerization, or the like). In various examples, a thermoset material (or a composition comprising one or more thermoset material(s) is an article of manufacture, an adhesive, a coating, an insulator, a building material, an elastomeric material, or an additive manufacturing material.
C08G 61/12 - Composés macromoléculaires contenant d'autres atomes que le carbone dans la chaîne principale de la macromolécule
C08G 61/08 - Composés macromoléculaires contenant uniquement des atomes de carbone dans la chaîne principale de la molécule, p. ex. polyxylylènes uniquement des atomes de carbone aliphatiques préparés par ouverture du cycle des composés carbocycliques des composés carbocycliques contenant une ou plusieurs doubles liaisons carbone-carbone dans le cycle
39.
MAPPING OF BRAIN NETWORKS FOR DETECTION OR CHARACTERIZATION OF PSYCHOLOGICAL CONDITIONS
The disclosed approach uses imaging data from a scan of a brain of a subject to generate a metric indicative of a characteristic of one or more functional networks in the brain. The metric, or data based on the metric, may be provided to a machine learning classifier to generate a prediction related to a psychological condition such as depression.
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
40.
FLUORINE-18 LABELED COMPOSITIONS AND THEIR USE IN IMAGING OF BIOLOGICAL TISSUE
A method for internal imaging of biological tissue in a subject by positron emission tomography (PET) or single photon emission computer tomography (SPECT), the method comprising: (i) administering to a subject an imaging agent that includes, at minimum, at least one fluorine-18 radionuclide bound directly or indirectly to a fluorophore, and (ii) imaging internal biological tissue of the subject by PET or SPECT. In further embodiments, the method includes (i) administering to a subject an imaging agent that includes at least one fluorine-18 radionuclide bound directly or indirectly to a fluorophore, and at least one biological entity (e.g., blood cell, peptide, nucleotide, aptamer, targeting agent, antibody, or antibody fragment) bound directly or indirectly to the fluorophore; and (ii) imaging internal biological tissue of the subject by PET or SPECT. In some embodiments, the method further includes simultaneously imaging the internal biological tissue by fluorescence imaging.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
Hydrophobic and oleophobic coatings, methods of making same, and uses of same. A coating can comprise one or more oleophobic and/or hydrophobic layer(s) disposed on a substrate, e.g., a fabric or the like. A layer comprises polymeric particles, which may be at least partially coalesced and/or crosslinked, comprising (co) polymer chains comprising silicon-containing pendant groups. A method of making a layer comprises: coating a substrate with an aqueous dispersion of the polymeric particles; and, optionally, curing the layer, e.g., to coalesce and/or crosslink the polymeric particles. A method of making the aqueous dispersion may comprise: forming a reaction mixture comprising one or more monomers comprising silicon-containing pendant groups; optionally, one or more comonomers; surfactant, and water. Coatings of the present disclosure have use in aerospace applications, automotive applications, building and construction, food processing, and electronics, or the like.
C09D 183/06 - Polysiloxanes contenant du silicium lié à des groupes contenant de l'oxygène
C09D 133/14 - Homopolymères ou copolymères d'esters d'esters contenant des atomes d'halogène, d'azote, de soufre ou d'oxygène en plus de l'oxygène du radical carboxyle
D06M 15/273 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone d'acides carboxyliques non saturésLeurs sels ou esters d'esters d'acides carboxyliques non saturés comportant des groupes époxy
Methods, device, system and one or more computer readable media having one or more computer programs with instructions to generate custom-fit garment patterns from a 3D body scan are disclosed. The patterns may be obtained by unwrapping the 3D body scan (3D image) into 2D using defined datapoints associated with the surface of a body in a target region. Patterns may be generated for different types of garments. The custom-fit garment patterns generated from the 3D body scan may be basic patterns, which may be further customized or modified as desired.
A verifier device in one embodiment is configured to communicate over one or more networks with a client device and a server device. The verifier device participates in a three-party handshake protocol with the client device and the server device in which the verifier device and the client device obtain respective shares of a session key of a secure session with the server device. The verifier device receives from the client device a commitment relating to the secure session with the server device, and responsive to receipt of the commitment, releases to the client device additional information relating to the secure session that was not previously accessible to the client device. The verifier device verifies correctness of at least one characterization of data obtained by the client device from the server device as part of the secure session, based at least in part on the commitment and the additional information.
Disclosed herein are mesoporous polymeric materials and methods for preparing and using the same. The mesoporous polymeric material comprises a network of cyclodextrin moieties crosslinked by a plurality of crosslinks.
A lipid nanoparticle (LNP) composition containing: (i) at least one glycan-containing lipid containing a glycan-containing moiety (S) linked to a lipid (L); (ii) at least one non-cationic lipid selected from charged and uncharged lipids; (iii) at least one cationic or ionizable lipid containing a secondary, tertiary, or quaternary amino group; and (iv) at least one therapeutic substance, such as a nucleic acid. Pharmaceutical compositions containing the LNP composition are also described. Methods of using the LNP composition by delivering a therapeutic substance to a subject are also described. Methods for targeted delivery of a therapeutic agent to a secondary lymphoid organ (SLO), brain, bone marrow, or specific cells (e.g., immune cells, precursor cells, or stem cells) of a subject are also described.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present disclosure relates to “Squash” and “Beetroot” nucleic acid aptamer molecules comprising certain nucleotide sequences and variations thereof. Also disclosed are molecular complexes comprising a fluorophore molecule and a nucleic acid aptamer molecule disclosed herein, isolated host cells comprising the molecular complexes, kits comprising a fluorophore and a nucleic acid aptamer, constructed DNA molecules encoding a nucleic acid aptamer molecule, expression systems, transgenic host cells, methods of detecting target molecules, RNA-based metabolite sensors, RNA-based ratiometric metabolite sensors, systems comprising RNA-based ratiometric metabolite sensors, and methods of generating a randomized aptamer library.
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
47.
CANCER INTERVENTION BY TARGETING GENOTYPIC DIFFERENCES USING CRISPR-CAS3 MEDIATED DELETION-EDITING
Provided are compositions and methods for selectively killing cancer cells. The method includes obtaining one or more biological samples from an individual, determining different nucleotide sequences in cancer and non-cancer cells from the biological sample using an algorithm to identify a candidate target sequence that is present in the cancer cells and not present in the non-cancer cells. Based on the different nucleotide sequences in the cancer cells relative to the non-cancer cells a CRISPR Cas3 system that includes a guide RNA targeted to an identified segment of the chromosome that is linked to the target sequence is degraded.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 30/10 - Alignement de séquenceRecherche d’homologie
Provided herein is a solid zwitterionic copolymer comprising repeat units of formulas (I) and (II). Compositions and articles comprising the copolymer are also provided, as are methods of making and using the copolymer. For example, layers of the copolymer find use in protecting a substrate from viral contamination, decreasing, reducing, or inhibiting viral proliferation on a substrate, and deactivating a virus on a substrate.
Provided herein is a solid zwitterionic copolymer comprising repeat units of formulas (I) and (II). Compositions and articles comprising the copolymer are also provided, as are methods of making and using the copolymer. For example, layers of the copolymer find use in protecting a substrate from viral contamination, decreasing, reducing, or inhibiting viral proliferation on a substrate, and deactivating a virus on a substrate.
C08F 226/06 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par un hétérocycle contenant de l'azote
C08J 7/06 - Revêtement par des compositions ne contenant pas de substances macromoléculaires
C08J 7/16 - Modification chimique par des composés polymérisables
C09D 5/00 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, caractérisées par leur nature physique ou par les effets produitsApprêts en pâte
C09D 139/04 - Homopolymères ou copolymères de monomères contenant des hétérocycles possédant de l'azote dans le cycle
49.
METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING HUMAN GUT MICROBES
Dysbiosis has been linked to diseases such as inflammatory bowel disease and obesity. Multi-omics studies have uncovered significant associations between microbiota genes and diseases. Many of these genes are exclusively expressed in non-model microbes such as Firmicutes/Clostridia. A pipeline for building microbial genetic manipulation systems would be a first step to manipulating these genes in vivo and causally connecting them with host diseases. The present technology relates generally to compositions and the methods of preparations thereof for genetically engineering gut-microbiota in vitro. The present technology further relates to uses of compositions in vivo.
Engineered phospholipase D mutants are described herein. Also described herein are methods of making engineered phospholipase D mutants. Additionally, methods of using engineered phospholipase D mutants are described.
Disclosed herein are tissue scaffold materials with microspheres of one density embedded in hydrogel of a different density. The disclosed materials have improved ability to facilitate cellular invasion and vascularization for wound healing and tissue regeneration. The inventors have found that materials having components with different densities promotes invasion of cells, including desirable cells such as fibroblasts and endothelial precursor cells, into the scaffold.
A61L 27/48 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges macromoléculaires
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
A61L 27/26 - Mélanges de matériaux macromoléculaires
A61L 27/44 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire
Provided herein are genetically engineered Rubisco enzymes and plants comprising the same. In one aspect, the disclosure features a genetically engineered plant comprising a Rubisco large subunit (LSU) comprising L2251 and K429Q amino acid substitution mutations, wherein the amino acid substitution mutations are numbered relative to the LSU of Nicotiana tabacum; and a Rubisco small subunit (SSU comprising N8G, V301, and E88Q amino acid substitution mutations, wherein the amino acid substitution mutations are numbered relative to the S-T2 subunit of Nicotiana tabacum.
Oligoesters and polyesters comprising one or more (e.g., a plurality) of crosslinkable and/or crosslinked clickable groups (e.g., capable of or formed by click reactions, respectively). methods of making same. and uses of same. In various examples, a method forms objects by irradiating compositions comprising crosslinkable oligoesters and polyesters and, optionally, solvent (e.g., crosslink-able solvent), crosslinking reagent, and/or crosslinking initiator, with electromagnetic radiation and/or by heating the compositions. In various examples, a method forms films, fibers, and other 3D objects. In various examples, biodegradable and/or elastomeric materials comprising crosslinked oligoesters and polyesters are useful in devices (e.g., microfluidic devices, lab on a chip, drug delivery devices, and the like), scaffolds, tissue grafts, skin patches, and the like. In various examples, methods are additive manufacturing methods, (e.g., 3D printing methods, such as, for example, digital light processing (DLP)).
Yissum Research Development Company of The Hebrew University of Jerusalem LTD (Israël)
Cornell University (USA)
Donald Danforth Plant Science Center (USA)
National Agricultural Research Organization (Ouganda)
Inventeur(s)
Colvin, John
Van Brunschot, Sharon L.
Swamy, Rekha
Seal, Susan
Morin, Shai
Malka, Osnat
Wintraube, Dor
Taylor, Nigel
Narayanan, Narayanan
Alicai, Titus
Kaweesi, Tadeo
Abrégé
The present disclosure is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The disclosure discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The disclosure also discloses methods and compositions for targeted genome editing in the pest in order to achieve a reduction in pest infestation through disruption of protein activity. The disclosure is also directed to methods for making transgenic plants that express the double stranded RNA molecules and targeted genome editing constructs for use in protecting plants from pest infestation.
Asymmetric arteriovenous grafts (AAVs) and uses thereof. In various examples, an AAV comprises a first AAV graft portion (e.g., arterial anastomosis portion or arterial anastomosis portion end), a second AAV graft portion (e.g., a venous anastomosis portion or a venous anastomosis end), a third AAV graft portion (e.g., a transition portion, such as, for example, a tapered transition portion, or a transition zone, such as, for example, a tapered transition zone), where a wall thickness of the third AAV graft portion decreases along at least a portion of the length of the third AAV graft portion and/or an inner diameter of the third AAV graft portion increases along at least a portion of the length of the third AAV graft portion. In various examples, an AAV graft is a compliant AAV graft. In various examples, a dialysis method uses an AAV graft (e.g., as an arteriovenous shunt or the like).
Alstroemeria plant particularly distinguished with vibrant coral colored flowers. The flowers on this plant have coral tepals with intense yellow highlights and little flecks of brown on the base of the inner tepals. Has a good longevity as a cut flower, continuous flowering from summer through fall, and winter-hardy from USDA zone 5 as described.
Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be PEGylated. The silica nanorings may be surface functionalized, which may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
A phonon-mediated upconversion method includes exciting a Raman phonon in a crystal by illuminating the crystal with a number of pump beams each having a same pump frequency equal to one half of a phonon frequency of the Raman phonon. The method also includes generating an upconverted beam by illuminating the crystal with at least one of the number of pump beams while the Raman phonon is at least partially excited. The upconverted beam has an upconverted frequency that is three times the pump frequency.
H01S 3/00 - Lasers, c.-à-d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
59.
SYSTEM AND DEVICES FOR MONITORING CELL-CONTAINING MATERIALS AND METHODS OF THEIR USE
The present application is directed to a system for collecting or extruding a cell-containing biological material. The system includes an extrusion/collection device comprising: an orifice and a chamber operably connected to the orifice and an electrical impedance spectroscopy (EIS) device, operably connected to the extrusion/collection device. The EIS device monitors biologically relevant attributes of a cell-containing biological material as it is extruded from or collected into the extrusion/collection device. Also disclosed are methods of using the system disclosed herein.
G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
G01N 1/10 - Dispositifs pour prélever des échantillons à l'état liquide ou fluide
G01N 27/06 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un liquide
The disclosure relates to compounds of the formula (I), (la), (II), (Ila), (llb), (llc), (lld), and (lle), compositions comprising such compounds, and the use of such compounds in imaging.
A polymeric composition comprising a polyurethane containing at least the following functional groups: (i) a five-membered or six-membered heterocyclic ring containing at least one ring heteroatom selected from nitrogen and oxygen atoms, and (ii) a zwitterionic group. Also described herein are articles made of the polymeric composition. Also described herein are methods for inactivating microbes and viruses on a surface of an object, the method comprising incorporating the anti-microbial polymeric composition into a surface of the object, either by constructing an object of the polymeric composition or by coating the surface of an object with the polymeric composition.
A01N 43/72 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec des atomes d'azote et des atomes d'oxygène ou de soufre, comme hétéro-atomes du cycle
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
Described in several embodiments herein are olfactory sensory neuron (OSN) derived extracellular vehicles (EVs), formulations thereof, and uses thereof. In some embodiments, the OSN derived extracellular vesicles are effective to increase the growth of neurons during regeneration. In some embodiments, the OSN derived EVs and/or formulations thereof are used to promote nerve regeneration, particularly peripheral nerve regeneration, and to treat nerve injury.
A fusion-power generation method includes co-circulating a first and a second charged-particle beam on a same orbit of a synchrotron. The method also includes, at completion of every Mth turn of the first charged-particle beam in the synchrotron, traversing the first charged-particle beam with the second charged-particle beam during an Nth turn of the second charged-particle beam. The method may include applying a radial electric field and a transverse magnetic field to each of the first the second charged-particle beam, such that each of quantities q1r0e (E0/v1+B0)/p1 and q2r0e(E0/v2+B0)/p2 equals one, where (i) q1, v1, and p1 are the charge, velocity, and momentum of each charged particle of the first charged-particle beam, respectively, (ii) q2, v2, and p2 are the charge, velocity, and momentum of each charged particle of the second changed-particle beam, respectively, and (iii) E0 and B0 are magnitudes of the applied electric field and magnetic field.
A method in an illustrative embodiment comprises obtaining an input data signal for a given individual, generating a noisy version of the input data signal, processing the noisy version of the input data signal in a denoising encoder-decoder neural network to generate a classification for the input data signal, and executing at least one automated action based at least in part on the generated classification. The automated action may comprise, for example, a remedial action, or another type of action. In some embodiments, the input data signal comprises at least one ECG data signal from at least one ECG sensor and/or at least one PPG data signal from at least one PPG sensor, although additional or alternative data signals can be used. The classification for the input data signal in some embodiments comprises, for example, a pain recognition classification providing a pain biomarker for the input data signal.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
A61B 5/0245 - Mesure du pouls ou des pulsations cardiaques utilisant des capteurs engendrant des signaux électriques
A61B 5/308 - Circuits d’entrée à cet effet spécialement adaptés à des utilisations particulières pour l’électrocardiographie [ECG]
A61B 5/318 - Modalités électriques se rapportant au cœur, p. ex. électrocardiographie [ECG]
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
66.
METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS
The present disclosure describes methods of treatment (e.g., combination treatment) by ferroptotic induction, as well as compositions and dosing regimens that are part of such methods. Surprisingly, it is presently found that delaying administration of a ferroptosis-inducing agent until after starting hormone therapy results in enhanced ferroptotic induction in a subject. Thus, in certain embodiments, combination therapies are presented herein that include multiple administration steps whereby a ferroptosis-inducing agent is administered some time after hormone therapy has begun.
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided are modified guide RNAs (gRNAs) for use with CRISPR Cas proteins. A modified guide RNA comprises at its 5′ or 3′end at least 5 nucleotides that comprise an inverted repeat sequence having a segment targeted to a spacer sequence in DNA. The inverted repeat sequence is configured so that it can concurrently be hybridized to the spacer sequence and to the complementary strand of the DNA comprising the spacer sequence when in the presence of the DNA and the Cas protein. The modified gRNA influences the Cas protein interaction with DNA.
Implanted medical devices need a mechanism of immobilization to surrounding tissues, which minimizes tissue damage while providing reliable long-term anchoring. This disclosure relates to techniques for patterning arbitrarily shaped 3D objects and to patterned balloon devices having micro-or nano-patterning on an outer surface of an inflatable balloon. The external pattern can provide enhanced friction and anchoring in an aqueous environment. Examples of these types of patterns are hexagonal arrays inspired by tree frogs, corrugated patterns, and microneedle patterns. The patterned balloon devices can be disposed between an implant and surrounding tissues to facilitate anchoring of the implant.
B29C 33/40 - Matière plastique, p. ex. mousse ou caoutchouc
B29C 33/42 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la forme de la surface de moulage, p. ex. par des nervures ou des rainures
B29C 33/56 - RevêtementsAgents de démoulage, de lubrification ou de séparation
B29C 37/00 - Éléments constitutifs, détails, accessoires ou opérations auxiliaires non couverts par le groupe ou
B29C 59/06 - Façonnage de surface, p. ex. gaufrageAppareils à cet effet par des moyens mécaniques, p. ex. par pressage en utilisant des tambours à vide
B29K 83/00 - Utilisation de polymères contenant dans la chaîne principale uniquement du silicium avec ou sans soufre, azote, oxygène ou carbone comme matière de moulage
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 217/22 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle contenant l'azote
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
71.
EXTRUSION OF AGRO-FOOD INDUSTRY BYPRODUCTS AND PROTEIN CONCENTRATES INTO VALUE-ADDED FOODS
The present invention relates to a process for preparing an edible foodstuff from food industry waste stream byproducts. This process involves the steps of: (i) combining, in an extruder, an extrusion formulation comprising a first food byproduct and at least one additional ingredient; (ii) introducing supercritical carbon dioxide (SC-CO2) into the extruder to mix with the first food byproduct and the at least one additional ingredient; and (iii) producing an edible foodstuff containing the first food byproduct and the at least one additional ingredient, where the edible foodstuff comprises an extrudate prepared under supercritical fluid extrusion (SCFX) conditions. The present invention also relates to a process for preparing an edible foodstuff from a protein concentrate. The present invention further relates to edible foodstuffs produced by the various processes disclosed herein.
A23L 19/00 - Produits à base de fruits ou de légumesLeur préparation ou leur traitement
A23P 30/34 - Soufflage ou expansion par décompression, p. ex. soufflage par explosionSoufflage ou expansion par traitement sous vide par extrusion-expansion
72.
NICOTINAMIDE RIBOSIDE TRIOLEATES CHLORIDE, COMPOSITIONS CONTAINING THIS COMPOUND, AND METHODS OF MAKING AND USING THIS COMPOUND
Nicotinamide riboside trioleates chloride (NRTOC1) is a novel hydrophobic derivative of nicotinamide riboside chloride. It can be used in a composition formulated for oral administration, preferably a beverage, such as a Ready-to-Drink (RTD) beverage scaled in a container or a powder formulated for reconstitution in a diluent to form a reconstituted beverage.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
The present invention relates to antimicrobial compounds isolated from Faecalibacterium prausnitzii supernatants, composition containing the compounds, and their use to inhibit bacterial growth or prevent bacterial infection, inhibit the virulence of N bacteria such as E. coli, and to treat diseases such as irritable bowel disease, Crohn's disease, and ulcerative colitis.
Lipid nanoparticles, compositions comprising lipid nanoparticles, and methods of making and using lipid nanoparticles. In various examples, a lipid nanoparticle: ionizable cationic amino lipid(s); PEG-lipid(s); phospholipid(s); and sterol(s); or a combination component comprising two or more groups having the functionality of two the aforementioned lipid components, which replaces those two aforementioned lipid components; and optionally, one or more cationic lipid component(s). In various examples, the lipid nanoparticle comprises one or more peptide(s), functionalized peptide(s), or the like, or any combination thereof, one or more of which may be therapeutic. In various examples, a composition, which may be a pharmaceutical composition, comprises a plurality of the lipid nanoparticles. In various examples, the lipid nanoparticles are used in method of delivering peptide(s), functionalized peptide(s), or the like, or any combination thereof. In various examples, the lipid nanoparticles are administered to an individual, which may be in need of treatment.
75.
METHODS FOR TREATING CANCER PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY BASED ON PATHOGNOMONIC LONG MOLECULE FOOTPRINTS OF BACKUP REPAIR PATHWAYS
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (USA)
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (USA)
CORNELL UNIVERSITY (USA)
Inventeur(s)
Powell, Simon
Imielinski, Marcin
Abrégé
The present disclosure provides methods for determining whether a cancer patient with homologous recombination deficiency will benefit from treatment with PARP inhibitors or platinum agents. These methods are based on screening a cancer patient for the presence of reciprocal structural variants (SVs) that comprise pairs of distant intra- or inter-chromosomal loci that contain exchanged genomic material.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
Described herein are nanoparticle conjugates that demonstrate enhanced penetration of tumor tissue (e.g., brain tumor tissue) and diffusion within the tumor interstitium, e.g., for treatment of cancer. Further described are methods of targeting tumor-associated macrophages, microglia, and/or other cells in a tumor microenvironment using such nanoparticle conjugates. Moreover, diagnostic, therapeutic, and theranostic (diagnostic and therapeutic) platforms featuring such nanoparticle conjugates are described for treating targets in both the tumor and surrounding microenvironment, thereby enhancing efficacy of cancer treatment. Use of the nanoparticle conjugates described herein with other conventional therapies, including chemotherapy, radiotherapy, immunotherapy, and the like, is also envisaged.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided herein are iPSC lines engineered to express 4R-tau and 4R-tau carrying the P301S MAPT mutation when differentiated into neurons. 4R-P301S neurons display progressive Tau inclusions upon seeding with Tau fibrils and recapitulate features of tauopathy phenotypes, including shared transcriptomic signatures, autophagic body accumulation, and impaired neuronal activity. A CRISPRi screening of genes associated with Tau pathobiology identified over 500 genetic modifiers of Tau-seeding-induced Tau propagation, including retromer VPS29 and the UFMylation cascade as top modifiers. In AD brains, the UFMylation cascade is altered in neurofibrillary-tangle-bearing neurons. Inhibiting the UFMylation cascade suppressed seeding-induced Tau propagation. Also provided herein is a platform to identify novel therapeutic strategies for 4R tauopathy.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
78.
SATSEQ: A MODULAR SYSTEM FOR COUPLING SATURATION MUTAGENESIS, DNA BARCODING, AND DEEP SEQUENCING
MEMORIAL SLOAN-KETTERING CANCER CENTER, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (USA)
Inventeur(s)
Laughney Bakhoum, Ashley
Deyell, Matthew
Bakhoum, Samuel F.
Li, Jun
Abrégé
SatSeqSatSeq technology which couples saturation mutagenesis, DNA barcoding, and deep sequencing. Disclosed are vectors, systems and methods for analysis of protein functions, validating drug targets, identifying on-target drug effects, identifying drugs that bind to genetically relevant variants, and/or identifying pathway-specific modulators of a pleiotropic gene, by applying the SatSeq technology.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
The present disclosure provides vaccines that include one or more HCMV viral Fc receptors (vFcyRs) or immunogenic fragments thereof and methods related thereto.
The present invention relates to a virus-like particle (VLP). The virus-like particle comprising a circular RNA molecule comprising: a first ligation sequence; an internal ribosomal entry site (IRES) coupled to an RNA molecule encoding one or more peptide(s), where the internal ribosomal entry site coupled to the RNA molecule encoding the one or more peptide(s) is positioned 3' to the first ligation sequence; a second ligation sequence positioned 3' to the internal ribosomal entry site coupled to the RNA molecule encoding the one or more peptide(s); and a plurality of one or more proteins that can self-assemble into a nanoparticle. Also disclosed are compositions and methods of making and using such virus-like particles.
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 15/67 - Méthodes générales pour favoriser l'expression
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
81.
IgE+ PLASMABLASTS AS A PREDICTIVE BIOMARKER OF ALLERGY
Methods of detecting IgE+ plasmablasts in a mammal are described herein. Also described herein are methods of predicting clinical allergy in a mammal. Additionally, methods of monitoring progression of an allergy along with methods of monitoring efficacy of treatment of an allergy are described.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
82.
MERGED SWITCHED-CAPACITOR PIEZOELECTRIC RESONATOR BASED POWER CONVERTER
A power converter includes a first stage, a second stage, and a piezoelectric-resonator electrically connected to the first stage and the second stage. At least one of the first stage and the second stage forms a switched capacitor converter circuit and includes a plurality of semiconductor switches and at least one flying capacitor. The power converter may be embodied as a unidirectional or bidirectional direct current-to-direct current (DC-DC), alternating current-to-direct current (AC-DC), or direct current-to-alternating current (DC-AC) power converter. The power converter may also include a control circuit configured to control operation of the semiconductor switches in a plurality of connected and open operation stages using variable or fixed switching frequencies.
H02M 1/00 - Détails d'appareils pour transformation
H02M 3/158 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs avec commande automatique de la tension ou du courant de sortie, p. ex. régulateurs à commutation comprenant plusieurs dispositifs à semi-conducteurs comme dispositifs de commande finale pour une charge unique
83.
MACROCYCLIC CHELATORS AND METHODS OF USE FOR THE SEPARATION OF RARE EARTH ELEMENTS
Water-soluble macrocyclic (metal-chelating) compositions having structure (1) wherein: A1, A2, A3, and A4are independently selected from O, S, and NRa, wherein Rais H or R, wherein R is a hydrocarbon group containing 1-12 carbon atoms; R1, R2, R3, and R4are independently selected from H, R, OH, COOH, OR, COOR, CN, and halogen atoms, wherein R1and R2and/or R3and R4are optionally interconnected to form a ring; R5and R6are independently selected from side chains of amino acids; and R7, R8, R9, R10, R11, and R12are independently selected from H, R, OH, COOH, OR, COOR, CN, and halogen atoms, wherein two of R7, R8, and R9(or two of R10, R11, and R12) are optionally interconnected to form a ring. Methods of using the above-described compositions for separation of RE elements are also described.
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C02F 5/12 - Traitement de l'eau avec des produits chimiques complexants ou des agents solubilisants pour l'adoucissement, la prévention ou l'élimination de l'entartrage, p. ex. par addition d'agents séquestrants en utilisant des substances organiques contenant de l'azote
C02F 1/68 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par addition de substances spécifiées, pour améliorer l'eau potable, p. ex. par addition d'oligo-éléments
C07K 5/078 - Dipeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
Described herein are compositions and methods for inducing immune tolerance comprising lipocoacervates loaded with a FasL species and IL-2 protein for controlled release of biologically active FasL and IL-2 over an extended time period.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
85.
FRUIT WITH INCREASED FRUIT SIZE, ANTIOXIDANTS, AND RESISTANCE TO BLOSSOM END ROT
BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (USA)
CORNELL UNIVERSITY (USA)
Inventeur(s)
Catala, Carmen
Nicolas, Philippe
Pattison, Richard
Abrégé
The present disclosure is directed to methods and compositions for increasing resistance to blossom end rot in fruit, increasing fruit size, and increasing antioxidant content in fruits. Embodiments of the disclosure also include plant cells, plants, and fruits including a modified ADP-glucose pyrophosphorylase (AGPase). Also included are nucleic acid constructs, and methods of breeding for enhanced blossom end rot resistance.
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
86.
IMPLANTABLE THERAPEUTIC DELIVERY SYSTEM AND METHODS THEREOF
Disclosed are an implantable therapeutic delivery system and methods of treatment utilizing the implantable therapeutic delivery system. The implantable therapeutic delivery system includes a nanofibrous core substrate including one or more internal spaces wherein one or more therapeutic agents is positioned in the one or more internal spaces; and an outer biocompatible polymeric coating surrounding said nanofibrous core substrate.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
87.
SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES
The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
88.
ZWITTERIONIC HYDROGELS FOR THE CULTURE, EXPANSION, AND PROTECTION OF CELLS AND CELL-DERIVED PRODUCTS
A hydrogel composition comprising a star polymer core containing at least three arms, wherein each arm contains a copolymer comprising zwitterionic monomer units and peptide-functionalized monomer units, wherein the peptide functions as a cell adhesive ligand, and wherein the hydrogel composition contains a biodegradable or non-biodegradable linker. Also described herein are methods of producing the hydrogel composition as well as methods of culturing and containing cells comprising combining cells with the hydrogel composition under conditions to promote cell survival, maintenance, cell product production, or cell growth.
A61L 24/04 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie contenant des matériaux macromoléculaires
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés
89.
SYSTEMS AND METHODS FOR EVALUATING THE BRAIN'S RESPONSE TO SPOKEN LANGUAGE
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Shah, Sudhin, A.
Schiff, Nicholas, D.
Lalor, Edmund, C.
Hill, Nichlas, Jeremy
Abrégé
The system and methods described herein diagnose the semantic processing capability of a subject by measuring the neural response of the subject to one or more naturalistic speech stimuli. The system measures the subject's temporal response function to the naturalistic speech by computing a statistical comparison between the subject's neural signal and a time series of semantic metric values corresponding to a transcript of the naturalistic speech stimulus. A diagnosis of the subject's semantic processing capability and the progression of the subject's Alzheimer's disease is then made based on an evaluation of the statistical comparison.
Research Foundation of the City University of New York (USA)
Cornell University (USA)
Inventeur(s)
Trasino, Steven
Gudas, Lorraine
Tang, Xiao-Han
Melis, Marta
Abrégé
Specifically, the invention relates to compositions and methods for treating liver ailments, such as compositions and methods for attenuating or ameliorating the development of alcoholic liver disease (ALD), hepatic steatosis, liver oxidative stress and/or hepatic lipogenesis associated with alcohol consumption in a subject by administering a retinoic acid receptor-beta (RARβ) agonist.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
An artificial cilium device includes a substrate and a voltage-actuated cilia-shaped structure attached at a proximal end to the substrate. The voltage-actuated cilia-shaped structure has a first layer of a first material and a second layer of a second material. The second layer of the second material includes an exposed surface that causes the cilia-shaped structure to, in a working medium, (a) change shape from a first shape to a second shape responsive to application of a first voltage and (b) change shape from the second shape to the first shape responsive to application of a second voltage different than the first voltage.
Disclosed herein are compounds including an albumin-binding domain and a Braf peptide, as well as pharmaceutically acceptable salts thereof. Furthermore, disclosed herein are methods for inducing an immune response in a subject, and methods of administering such compounds to induce an immune response in a subject.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Methods of producing one or more trisubstituted lactone(s) comprising contacting a reaction mixture comprising one or more 2,2,3-trisubstituted epoxide(s) and one or more catalyst(s) with carbon monoxide. A catalyst may comprise a cationic Lewis acid and an anionic metal carbonyl. Methods may be regioselective and/or stereoselective. Trisubstituted lactones, which may be 3,3,4-trisubstituted β-lactones. Compositions comprising trisubstituted lactone(s). Polymers formed from trisubstituted lactone(s).
B01J 31/14 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques contenant des composés organométalliques ou des hydrures métalliques d'aluminium ou de bore
Lipocoacervates and compositions comprising lipocoacervates, methods of making and using same. A lipocoacervate comprises a coacervate phase and a lipid or lipids, where the lipid(s) is/are disposed on at least a portion of an exterior surface of the coacervate phase, and optionally, one or more biomolecules. In various examples, a coacervate phase comprises cationic component(s), such as, for example, polycations, such as, for example, chitosan, spermine, spermidine, positively-charged polymers, positively-charged proteins, and any combination thereof, and anionic component(s), such as, for example, polyanions, such as, for example, glycosaminoglycans, nucleic acids, negatively-charged proteins, and any combination thereof. In various examples, an anionic component is a biomolecule. In various examples, a lipocoacervate is made by contacting a coacervate composition with a lipid composition, where lipocoacervate(s) or a lipocoacervate composition is/are formed. In various examples, lipocoacervates or lipocoacervate composition(s) is/are used to intracellularly deliver a biomolecule or biomolecules to an individual.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A digital image detection apparatus and method of use are disclosed. The apparatus may include an array of photon detectors, configured to receive photons reflected from a target scene and a plurality of first arrival differential (FAD) units, where each FAD units is configured to receive a first input from a first photon detector in the array and a second input from a second photon detector. Each FAD unit may include a set-reset (“SR”) latch, configured to receive the first input and the second input and to determine which of the first input and the second input arrives earlier in time, and a counter control unit, configured to receive an output from the SR latch and increment a differential count based on the output.
The present invention relates to a microfluidic device for extracting and isolating DNA from cells. The device includes a support having an inlet port for receiving a sample containing a cell, an outlet port for dispensing DNA isolated from the cell, and a microfluidic channel disposed within the support and extending from the inlet port to the outlet port. The microfluidic channel includes a micropillar array, an inflow channel disposed between the inlet port and the micropillar array, and an outflow channel disposed between the micropillar array and the outlet port. The micropillar array includes micropillars spatially configured to entrap, by size exclusion, the cell, to immobilize DNA released from the cell, and to maintain the immobilized DNA in elongated or non-elongated form when hydrodynamic force is applied to the microfluidic channel. Systems and methods of making and using the device are also provided herein.
The present disclosure is directed to Compositions comprising a population of multivalent viral particles are described herein. Also described herein are immunogenic compositions comprising a population of multivalent viral particles. Additionally, methods of making a multivalent immunogenic composition comprising a population of multivalent viral particles are described. Lastly, methods of using an immunogenic composition to elicit an immune response in a subject are described herein.
A magnetically actuated cranial distraction system comprises a bioresorbable distractor device, a guide rod, and a magnetically actuated ratchet. The bioresorbable distractor device is configured to induce cranial bone growth and includes a fixed base member and a mobile base member. The guide rod is coupled with the bioresorbable distractor device and guides movement of the mobile base member relative to the fixed base member. The magnetically actuated ratchet is configured to be magnetically activated from outside a patient to selectively move the mobile base member away from the fixed base member.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Schiff, Nicholas
Baker, Jonathan
Butson, Christopher
Janson, Andrew
O'Sullivan, Kyle
Henderson, Jaimie
Choi, Eun Young
Rutt, Brian
Radovan, Matthew
Su, Jason
Abrégé
Methods and devices for vector-based targeting of the human central thalamus (CT) to guide deep brain stimulation (DBS) are disclosed. In some examples, electrode(s) each with a plurality contacts are provided. A three-dimensional orientation of a dominant axis of a central lateral nucleus dorsal tegmental tract medial component (CL/DTTm) fiber bundle of a human subject is determined. The contacts of the electrode(s) are positioned in the subject's CT fibers in substantial alignment with the three-dimensional orientation. An electrical stimulus is applied to the contacts to selectively activate the CT fibers. The positioning and the applying are carried out to maximize activation of a central lateral nucleus and medial dorsal tegmental tract fiber pathway in the subject and to minimize activation of a centromedian-parafascicularis fiber pathway in the subject. Methods and devices for surgical planning involving for vector-based targeting of the human CT to guide DBS are also disclosed.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
100.
METHODS FOR TREATING A SUBTYPE OF COLORECTAL CANCER
Sanford Burnham Prebys Medical Discovery Institute (USA)
Inventeur(s)
Moscat-Guillen, Jorge
Diaz-Meco Conde, Maria T.
Duran-Molina, Maria Angeles
Martinez-Ordonez, Anxo
Abrégé
This invention relates generally to methods for determining a subject having or is suspected of having a subtype of colorectal cancer and methods for treating the subject.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
